ICMR fast-tracking efforts to launch ‘COVAXIN’ for public use by 15th August
In partnership with Hyderabad based Bharat Biotech, the Indian Council of Medical Research (ICMR) has selected 12 institutes for the Phase-I and Phase-II clinical trials of the first indigenously developed COVID-19 vaccine BBV152 (commonly known as COVAXIN).
After successful completion of human clinical trials, the ICMR has set a target to launch the COVAXIN for the public health uses, latest by August 15, this was reported in the media as per a letter by ICMR to the 12 selected institutes.
Earlier this week, the Drug Controller General of India (DCGI) has given approval for Phase I and Phase II human clinical trials for COVID-19 vaccine ‘COVAXIN’. In association with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV) Pune, COVAXIN is developed by Hyderabad based vaccine & bio-therapeutics manufacturer-Bharat Biotech. At NIV Pune, the strain of SARS-CoV-2 was isolated before being transferred to Bharat Biotech. The vaccine is developed at the high containment facility of Bharat Biotech- BSL-3 (Bio Safety Level 3).
COVAXIN is the first indigenously developed COVID-19 vaccine to be approved for Human Clinical Trials.
Zydus Healthcare gets DCGI nod for Human Trials
On 2nd July 2020, the DCGI of India has given permission to Ahmedabad based Cadila Healthcare Limited (commonly known as Zydus Healthcare) for the human clinical trials of its indigenously developed COVID-19 vaccine.